Major developments in cancer drug approvals, healthcare safety warnings, and disease prevention efforts emerge across oncology, infectious disease, and immunization sectors.

Sacituzumab govitecan receives first-line approval for metastatic triple-negative breast cancer, marking the first antibody-drug conjugate (ADC) approved for this indication regardless of PD-L1 inhibitor status, expanding treatment options for patients.

Africa's CDC raises Ebola response funding requirements to $1.4 billion—triple the previous estimate—highlighting critical gaps in pandemic preparedness and resource allocation across the continent.

NHS systems lag behind rapid growth of online prescribing platforms, creating safety gaps that leave clinicians without essential patient information needed for safe medication decisions, warns HSSIB.

U.S. Supreme Court significantly limits thousands of state-court lawsuits against Bayer over alleged Roundup cancer risks, reducing the company's litigation exposure related to glyphosate safety warnings.

New research links combined oral contraceptives to higher emotional eating scores during active pill use, though clinical significance of the finding remains uncertain and requires further investigation.

Bimekizumab demonstrates comparable drug survival rates to interleukin-23 inhibitors in psoriasis treatment after IL-17 inhibitor failure, offering patients additional therapeutic alternatives.

Analysis reveals gender parity in post-anaphylaxis mortality and hospital outcomes, with no significant differences in hospital stays or charges between male and female patients.

Denmark's influenza vaccination coverage in type 1 diabetes patients remains significantly below WHO's 75% target, with only 16.9% coverage in children and 41.8% in adults as of 2022-2023.